Differential regulation by glucocorticoid of interleukin-13-induced eosinophilia, hyperresponsiveness, and goblet cell hyperplasia in mouse airways.
Interleukin (IL)-13 induces important features of bronchial asthma such as eosinophilic infiltration, airway hyperresponsiveness (AHR), and mucus hypersecretion. Although glucocorticoids suppress airway inflammation and remain the most effective therapy for asthma, the effects of glucocorticoids on the IL-13-dependent features are unknown. We studied the effects of dexamethasone on eotaxin production, eosinophil accumulation, goblet cell hyperplasia, and AHR after IL-13 administration into the airways of mice in vivo. MUC5AC gene expression, a marker of goblet cell hyperplasia, was also analyzed. IL-13 alone dose dependently induced AHR. Treatment with dexamethasone inhibited eotaxin expression and completely abolished eosinophil accumulation, but it did not affect AHR, MUC5AC overexpression, or goblet cell hyperplasia induced by IL-13. The effects of tumor necrosis factor-alpha on IL-13-induced AHR were also examined. Tumor necrosis factor-alpha did not affect AHR despite marked enhancement of eosinophil infiltration in IL-13-treated mice. These findings suggest that glucocorticoid is not sufficient to suppress IL-13-induced AHR or goblet cell hyperplasia and that eotaxin expression and eosinophilic inflammation do not have a causal relationship to the induction of AHR or goblet cell hyperplasia by IL-13. Control of steroid-resistant features induced by IL-13, including AHR and mucus production, may provide new therapeutic modalities for asthma.
Kibe
Atsuko
A
Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Inoue
Hiromasa
H
Fukuyama
Satoru
S
Machida
Kentaro
K
Matsumoto
Koichiro
K
Koto
Hiroshi
H
Ikegami
Tomomi
T
Aizawa
Hisamichi
H
Hara
Nobuyuki
N
D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002452:Cell Count; D054413:Chemokine CCL11; D019742:Chemokines, CC / Q000235:genetics; D003907:Dexamethasone / Q000494:pharmacology; D004802:Eosinophilia / Q000139:chemically induced*; D004804:Eosinophils / Q000473:pathology; D005938:Glucocorticoids / Q000494:pharmacology*; D020397:Goblet Cells / Q000187:drug effects* / Q000473:pathology*; D006965:Hyperplasia; D018793:Interleukin-13 / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D055271:Mucin 5AC; D009077:Mucins / Q000235:genetics; D009093:Mucus / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D012130:Respiratory Hypersensitivity / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
C515457:Ccl11 protein, mouse; D054413:Chemokine CCL11; D019742:Chemokines, CC; D005938:Glucocorticoids; D018793:Interleukin-13; C524679:Muc5ac protein, mouse; D055271:Mucin 5AC; D009077:Mucins; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D003907:Dexamethasone